| References |
Alderman, C.P., Lee, P.C., Comment: serotonin syndrome associated with combined sertraline-amitriptyline treatment (1996) Ann. Pharmacother., 30 (12), pp. 1499-1500; Baker, D.R., Kasprzyk-Hordern, B., Multi-residue determination of the sorption of illicit drugs and pharmaceuticals to wastewater suspended particulate matter using pressurised liquid extraction, solid phase extraction and liquid chromatography coupled with tandem mass spectrometry (2011) J. Chromatogr. A, 1218 (44), pp. 7901-7913; Baker, D.R., Barron, L., Kasprzyk-Hordern, B., Illicit and pharmaceutical drug consumption estimated via wastewater analysis. Part A: chemical analysis and drug use estimates (2014) Sci. Total Environ., 487, pp. 629-641; Bansal, D., Bhansali, A., Hota, D., Chakrabarti, A., Dutta, P., Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial (2009) Diabet. Med., 26 (10), pp. 1019-1026; Barbui, C., Hotopf, M., Amitriptyline v. The rest: still the leading antidepressant after 40 years of randomised controlled trials (2001) Br. J. Psychiatry, 178, pp. 129-144; Bhandari, P.R., Zebrafish: a novel model in neuropsychopharmacological research (2016) Int. J. Basic Clin. Pharmacol., 5 (3), pp. 546-557; Boyer, E.W., Shannon, M., The serotonin syndrome (2005) N. Engl. J. Med., 352 (11), pp. 1112-1120; Burke, N.N., Finn, D.P., Roche, M., Chronic administration of amitriptyline differentially alters neuropathic pain-related behaviour in the presence and absence of a depressive-like phenotype (2015) Behav. Brain Res., 278, pp. 193-201; Daly, J.M., Wilens, T., The use of tricyclic antidepressants in children and adolescents (1998) Pediatr. Clin. N. Am., 45 (5), pp. 1123-1135; Dougherty, J.A., Young, H., Shafi, T., Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine (2002) Ann. Pharmacother., 36 (10), pp. 1647-1648; Dunkley, E.J., Isbister, G.K., Sibbritt, D., Dawson, A.H., Whyte, I.M., The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity (2003) QJM, 96 (9), pp. 635-642; Dvir, Y., Smallwood, P., Serotonin syndrome: a complex but easily avoidable condition (2008) Gen. Hosp. Psychiatry, 30 (3), pp. 284-287; Egan, J., Earley, C.J., Leonard, B.E., The effect of amitriptyline and mianserine (Org. GB94) on food motivated behaviour of rats trained in a runway: possible correlation with biogenic amine concentration in the limbic system (1979) Psychopharmacology, 61 (2), pp. 143-147; Ellis, G.P., West, G.B., Progress in Medicinal Chemistry (2011), Elsevier; Geneva Pharmaceuticals, Amitriptyline Hydrochloride Tablets, USP Prescribing Information (2001), Broomfield CA; Gillman, P.K., A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action (2006) Biol. Psychiatry, 59 (11), pp. 1046-1051; Goldsmith, P., Zebrafish as a pharmacological tool: the how, why and when (2004) Curr. Opin. Pharmacol., 4 (5), pp. 504-512; Grossman, L., Utterback, E., Stewart, A., Gaikwad, S., Chung, K.M., Suciu, C., Wong, K., Kalueff, A.V., Characterization of behavioral and endocrine effects of LSD on zebrafish (2010) Behav. Brain Res., 214 (2), pp. 277-284; Haberzettl, R., Bert, B., Fink, H., Fox, M.A., Animal models of the serotonin syndrome: a systematic review (2013) Behav. Brain Res., 256, pp. 328-345; Halmi, K.A., Eckert, E., LaDu, T.J., Cohen, J., Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline (1986) Arch. Gen. Psychiatry, 43 (2), pp. 177-181; Hughes, S.R., Kay, P., Brown, L.E., Global synthesis and critical evaluation of pharmaceutical data sets collected from river systems (2013) Environ. Sci. Technol., 47 (2), pp. 661-677; Jackson, J.L., Shimeall, W., Sessums, L., DeZee, K.J., Becher, D., Diemer, M., Berbano, E., O'Malley, P.G., Tricyclic antidepressants and headaches: systematic review and meta-analysis (2010) BMJ, 341; Jang, S.W., Liu, X., Chan, C.B., Weinshenker, D., Hall, R.A., Xiao, G., Ye, K., Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity (2009) Chem. Biol., 16 (6), pp. 644-656; Jarosik, J., Legutko, B., Unsicker, K., von Bohlen Und Halbach, O., Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy (2007) Exp. Neurol., 204 (1), pp. 20-28; Kalueff, A.V., Gallagher, P.S., Murphy, D.L., Are serotonin transporter knockout mice ‘depressed’?: hypoactivity but no anhedonia (2006) Neuroreport, 17 (12), pp. 1347-1351; Kalueff, A.V., Fox, M.A., Gallagher, P.S., Murphy, D.L., Hypolocomotion, anxiety and serotonin syndrome-like behavior contribute to the complex phenotype of serotonin transporter knockout mice (2007) Genes Brain Behav., 6 (4), pp. 389-400; Kalueff, A.V., Stewart, A.M., Gerlai, R., Zebrafish as an emerging model for studying complex brain disorders (2014) Trends Pharmacol. Sci., 35 (2), pp. 63-75; Kasprzyk-Hordern, B., Dinsdale, R.M., Guwy, A.J., Multiresidue methods for the analysis of pharmaceuticals, personal care products and illicit drugs in surface water and wastewater by solid-phase extraction and ultra performance liquid chromatography-electrospray tandem mass spectrometry (2008) Anal. Bioanal. Chem., 391 (4), pp. 1293-1308; Katz, R.J., Hersh, S., Amitriptyline and scopolamine in an animal model of depression (1981) Neurosci. Biobehav. Rev., 5 (2), pp. 265-271; Kyzar, E.J., Collins, C., Gaikwad, S., Green, J., Roth, A., Monnig, L., El-Ounsi, M., Kalueff, A.V., Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology (2012) Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 37 (1), pp. 194-202; Lehmann, L.S., Bowden, C.L., Redmond, F.C., Stanton, B.C., Amitriptyline and nortriptyline response profiles in unipolar depressed patients (1982) Psychopharmacology, 77 (2), pp. 193-197; Levin, E.D., Bencan, Z., Cerutti, D.T., Anxiolytic effects of nicotine in zebrafish (2007) Physiol. Behav., 90 (1), pp. 54-58; Lieschke, G.J., Currie, P.D., Animal models of human disease: zebrafish swim into view (2007) Nat. Rev. Genet., 8 (5), pp. 353-367; Lockhart, P., Guthrie, B., Trends in primary care antidepressant prescribing 1995–2007: a longitudinal population database analysis (2011) Br. J. Gen. Pract., 61 (590), pp. e565-e572; Mason, P.J., Morris, V.A., Balcezak, T.J., Serotonin syndrome. Presentation of 2 cases and review of the literature (2000) Medicine (Baltimore), 79 (4), pp. 201-209; Maximino, C., Lima, M.G., Araujo, J., Oliveira, K.R.M., Herculano, A.M., Stewart, A.M., Kyzar, E.J., Kalueff, A.V., The Serotonergic System of Zebrafish: Genomics, Neuroanatomy and Neuropharmacology (2013); Maximino, C., Puty, B., Benzecry, R., Araujo, J., Lima, M.G., de Jesus Oliveira Batista, E., Renata de Matos Oliveira, K., Herculano, A.M., Role of serotonin in zebrafish (Danio rerio) anxiety: relationship with serotonin levels and effect of buspirone, WAY 100635, SB 224289, fluoxetine and para-chlorophenylalanine (pCPA) in two behavioral models (2013) Neuropharmacology, 71, pp. 83-97; Moore, R.A., Derry, S., Aldington, D., Cole, P., Wiffen, P.J., Amitriptyline for neuropathic pain and fibromyalgia in adults (2012) Cochrane Database Syst. Rev., 12; Neelkantan, N., Mikhaylova, A., Stewart, A.M., Arnold, R., Gjeloshi, V., Kondaveeti, D., Poudel, M.K., Kalueff, A.V., Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds (2013) ACS Chem. Neurosci., 4 (8), pp. 1137-1150; Nguyen, T., Shapiro, D.A., George, S.R., Setola, V., Lee, D.K., Cheng, R., Rauser, L., O'Dowd, B.F., Discovery of a novel member of the histamine receptor family (2001) Mol. Pharmacol., 59 (3), pp. 427-433; Nguyen, M., Yang, E., Neelkantan, N., Mikhaylova, A., Arnold, R., Poudel, M.K., Stewart, A.M., Kalueff, A.V., Developing ‘integrative’ zebrafish models of behavioral and metabolic disorders (2013) Behav. Brain Res., 256, pp. 172-187; Nisijima, K., Shimizu, M., Abe, T., Ishiguro, T., A case of serotonin syndrome induced by concomitant treatment with low dose trazodone and amitriptyline and lithium (1996) Int. Clin. Psychopharmacol., 11 (4), pp. 289-290; Olgun, H., Yildirim, Z.K., Karacan, M., Ceviz, N., Clinical, electrocardiographic, and laboratory findings in children with amitriptyline intoxication (2009) Pediatr. Emerg. Care, 25 (3), pp. 170-173; Owens, M.J., Morgan, W.N., Plott, S.J., Nemeroff, C.B., Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites (1997) J. Pharmacol. Exp. Ther., 283 (3), pp. 1305-1322; Pandey, D.K., Mahesh, R., Kumar, A.A., Rao, V.S., Arjun, M., Rajkumar, R., A novel 5-HT(2A) receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants (2010) Pharmacol. Biochem. Behav., 94 (3), pp. 363-373; Perez-Escudero, A., Vicente-Page, J., Hinz, R.C., Arganda, S., de Polavieja, G.G., idTracker: tracking individuals in a group by automatic identification of unmarked animals (2014) Nat. Methods, 11 (7), pp. 743-748; Petrie, B., Barden, R., Kasprzyk-Hordern, B., A review on emerging contaminants in wastewaters and the environment: current knowledge, understudied areas and recommendations for future monitoring (2015) Water Res., 72, pp. 3-27; Porsolt, R.D., Le Pichon, M., Jalfre, M., Depression: a new animal model sensitive to antidepressant treatments (1977) Nature, 266 (5604), pp. 730-732; Rauser, L., Savage, J.E., Meltzer, H.Y., Roth, B.L., Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor (2001) J. Pharmacol. Exp. Ther., 299 (1), pp. 83-89; Riehl, R., Kyzar, E., Allain, A., Green, J., Hook, M., Monnig, L., Rhymes, K., Kalueff, A.V., Behavioral and physiological effects of acute ketamine exposure in adult zebrafish (2011) Neurotoxicol. Teratol., 33 (6), pp. 658-667; Sackerman, J., Donegan, J.J., Cunningham, C.S., Nguyen, N.N., Lawless, K., Long, A., Benno, R.H., Gould, G.G., Zebrafish behavior in novel environments: effects of acute exposure to anxiolytic compounds and choice of Danio rerio line (2010) Int. J. Comp. Psychol., 23 (1), pp. 43-61. , (sponsored by the International Society for Comparative Psychology and the University of Calabria); Samartzis, L., Savvari, P., Kontogiannis, S., Dimopoulos, S., Linezolid is associated with serotonin syndrome in a patient receiving amitriptyline, and fentanyl: a case report and review of the literature (2013) Case Rep. Psychiatry, 2013, p. 5; Segal, B., Duffy, L.K., Biobehavioral Effects of Psychoactive Drugs (1999); Shioda, K., Nisijima, K., Yoshino, T., Kato, S., Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine (2004) Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 28 (4), pp. 633-640; Sindrup, S.H., Jensen, T.S., Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action (1999) Pain, 83 (3), pp. 389-400; Sindrup, S.H., Gram, L.F., Brosen, K., Eshoj, O., Mogensen, E.F., The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms (1990) Pain, 42 (2), pp. 135-144; Singer, M.L., Oreschak, K., Rhinehart, Z., Robison, B.D., Anxiolytic effects of fluoxetine and nicotine exposure on exploratory behavior in zebrafish (2016) PeerJ, 4; Sriram, D., Medicinal Chemistry (2010), Pearson Education India; Sternbach, H., The serotonin syndrome (1991) Am. J. Psychiatry, 148 (6), pp. 705-713; Stewart, A., Gaikwad, S., Hart, P., Kyzar, E., Roth, A., Kalueff, A.V., Experimental models for anxiolytic drug discovery in the era of omes and omics (2011) Expert Opin. Drug Discovery, 6 (7), pp. 755-769; Stewart, A., Riehl, R., Wong, K., Green, J., Cosgrove, J., Vollmer, K., Kyzar, E., Kalueff, A.V., Behavioral effects of MDMA (‘ecstasy’) on adult zebrafish (2011) Behav. Pharmacol., 22 (3), pp. 275-280; Stewart, A., Wu, N., Cachat, J., Hart, P., Gaikwad, S., Wong, K., Utterback, E., Kalueff, A.V., Pharmacological modulation of anxiety-like phenotypes in adult zebrafish behavioral models (2011) Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 35 (6), pp. 1421-1431; Stewart, A.M., Cachat, J., Gaikwad, S., Robinson, K.S., Gebhardt, M., Kalueff, A.V., Perspectives on experimental models of serotonin syndrome in zebrafish (2013) Neurochem. Int., 62 (6), pp. 893-902; Stewart, A.M., Gerlai, R., Kalueff, A.V., Developing highER-throughput zebrafish screens for in-vivo CNS drug discovery (2015) Front. Behav. Neurosci., 9, p. 14; Tatsumi, M., Groshan, K., Blakely, R.D., Richelson, E., Pharmacological profile of antidepressants and related compounds at human monoamine transporters (1997) Eur. J. Pharmacol., 340 (2-3), pp. 249-258; Togola, A., Budzinski, H., Multi-residue analysis of pharmaceutical compounds in aqueous samples (2008) J. Chromatogr. A, 1177 (1), pp. 150-158; Vainio, A., Ollila, J., Matikainen, E., Rosenberg, P., Kalso, E., Driving ability in cancer patients receiving long-term morphine analgesia (1995) Lancet, 346 (8976), pp. 667-670; Vrethem, M., Boivie, J., Arnqvist, H., Holmgren, H., Lindstrom, T., Thorell, L.H., A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics (1997) Clin. J. Pain, 13 (4), pp. 313-323; Watson, C.P., Vernich, L., Chipman, M., Reed, K., Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial (1998) Neurology, 51 (4), pp. 1166-1171; Werling, L.L., Keller, A., Frank, J.G., Nuwayhid, S.J., A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder (2007) Exp. Neurol., 207 (2), pp. 248-257; Westerfield, M., A Guide for the Laboratory Use of Zebrafish (Danio rerio), The Zebrafish Book (2000), pp. 4-5.2. , University of Oregon Press Eugene; Wong, K., Stewart, A., Gilder, T., Wu, N., Frank, K., Gaikwad, S., Suciu, C., Kalueff, A.V., Modeling seizure-related behavioral and endocrine phenotypes in adult zebrafish (2010) Brain Res., 1348, pp. 209-215; Zychowska, M., Rojewska, E., Przewlocka, B., Mika, J., Mechanisms and pharmacology of diabetic neuropathy–experimental and clinical studies (2013) Pharmacol. Rep., 65 (6), pp. 1601-1610 |